Celgene touts mid-stage psoriasis results

Researchers for Celgene are changing the dosing and duration of their tests of an experimental psoriasis drug after seeing a significant reduction in severity and symptoms in a mid-stage study. A 260-patient study of CC-10004 demonstrated that 24.4 percent of patients treated with 20 milligrams of CC-10004 every 12 hours had a 75 percent or greater reduction in psoriasis severity and symptoms. A placebo registered a 10.3 percent reduction. Patients can now get doses of 30 mgs for up to six months and Celgene will expand the trial to include related conditions. No serious side effects were reported.

- see this release
- check out the AFX report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.